Electroporation (EP)-mediated DNA immunization can elicit effective immune responses in a variety of animals, and is widely used in research studies and clinical trials. However, high-pulse voltage, high DNA dose and multiple immunizations are still required to achieve considerable immune responses. To further improve the efficiency of EP-mediated DNA immunization, many parameters have been tried and optimized in recent years. In our early research, we found that the short noncoding DNA fragments (sf-DNA) can significantly enhance EP-mediated transgene expression of reporter genes. In this study, we tested the effect of sf-DNA on the immune potency of EP-mediated hepatitis B virus (HBV) DNA vaccination in a mouse model. The results show that the use of sf-DNA in EP-mediated HBV DNA vaccination leads to an enhanced expression of the HBV surface antigen, resulting in higher cellular and humoral responses. Furthermore, the immune responses in the sf-DNA-mediated 120 V cm − 1 EP immunization group were higher than that of the 200 V cm − 1 EP without sf-DNA groups. These data suggest that the sf-DNA can be used as an effective helper molecule to improve the immune response of EP-mediated HBV DNA vaccination, which may make the EP-mediated DNA vaccination more effective and suitable for animal and clinical application.
INTRODUCTION
DNA vaccines encoding specific antigens have been shown to elicit cellular as well as humoral immune responses in various animal models, providing possible solutions for the prevention or treatment of cancer and infectious diseases. [1] [2] [3] Owing to the endogenous production of viral proteins, the immune response generated by DNA vaccination closely resembles that induced by natural infection. This intracellular synthesis is especially important when inducing cell-mediated immunity, which is critical for the immune clearance of the pathogen by cytotoxic T lymphocytes. 4 Therefore, DNA vaccination is worth pursuing as a treatment for chronic infectious diseases such as chronic hepatitis B virus (HBV) infection.
Recent studies have shown, however, that the immunogenicity generated by naked plasmid DNA intramuscular (i.m.) injections used for protection or for therapeutic purposes may not be sufficient. [5] [6] [7] Therefore, researchers have searched for various strategies to improve the immunogenicity of plasmid DNA vaccines, including vector modification to enhance antigen expression, the use of vaccine adjuvant and the modification of professional antigen-presenting cells. [8] [9] [10] However, even when these methods are used, only a small percentage of plasmid DNA enters cells and becomes functional, lending to low immune induction efficiency when used in humans or large animals. Therefore, increasing the in vivo transfection efficiency may be the key to improving the immunogenicity of DNA vaccines. As for plasmid DNA transfection, facilitating the entrance of DNA into cells in general (for example, muscle cells) and targeting DNA for uptake by specific types of cells (for example, antigen-presenting cells) are the two main strategies to improve DNA vaccine potency. 2, 9, 11 Currently, various approaches such as microspheres, 12 gene gun, 13,14 ultrasound 15 and electroporation (EP) [16] [17] [18] are used to increase the efficiency of delivery of DNA into cells.
EP, which is believed to associate cell membrane permeability with electrophores, has been consistently successful in both in vitro and in vivo plasmid DNA transfection. 19, 20 It can improve i.m. DNA vaccination efficacy in various animal models by prompting the quick onset and boosting the magnitude and duration of both humoral and cellular immune responses. 17, [21] [22] [23] Several ongoing clinical trials using EP for DNA vaccine immunization clearly demonstrate the safety and reproducibility of this method. 24, 25 For big animals and human beings, however, high-pulse voltage, high DNA vaccine dose and multiple immunizations are still required to achieve considerable immune responses in vivo. 17, [26] [27] [28] To make the EP-mediated DNA immunization more efficient and feasible, other approaches such as plasmid-encoded cytokine adjuvants have been pursued avidly to further improve the efficiency of EP-mediated gene delivery. 26, 29 In our early research, we found that the presence of short noncoding DNA fragments (sf-DNA) in plasmid DNA injection solution significantly enhanced EP-mediated transgene expression of reporter genes up to 20-fold. This effect was related to properties of sf-DNA (such as length, structure and dose) and the most effective parameters of sf-DNA are 300 bp in length and 2:1 (sf-DNA/plasmid DNA) in mass ratio. 30 The protein expressed in the sf-DNA mediated 120 V cm − 1 EP group was four times higher than that of the 200 V cm − 1 control group (EP without sf-DNA), thus bolstering our confidence in the potency of sf-DNA on EP-mediated DNA vaccine immunization.
In this study, we evaluated the effect of sf-DNA on improving the immune potency of EP-mediated HBV DNA vaccination in mouse model. The gWIZ-GFP encoding green fluorescent protein (GFP) and pSEAP2 control vector (pSEAP) encoding secreted alkaline phosphatase (SEAP) were used as reporter genes to validate the effect of sf-DNA on EP-mediated plasmid DNA delivery in mouse muscle tissue. The plasmid DNA encoding HBV surface antigen (HBSAg) preS2-S (pCS) was used as the DNA vaccine for the assessment of the effect of sf-DNA on EP-mediated immunization. The HBsAg expressed in immunized tissue, the antiHBSAg antibody (HBsAb) in serum and the HBsAg-specific splenic interferon (IFN)-γ-secreting cells were tested at designated time points after EP-mediated immunization.
RESULTS
The effect of sf-DNA on EP-mediated reporter plasmid DNA delivery One day after EP-mediated gWIZ-GFP delivery, the level of GFP expressed in muscle tissue was evaluated using eXplore Optix system and the results are presented in Figure 1a . Based on the fluorescence intensity, we found that the expression level of GFP in sf-DNA group (right leg) was significantly higher than that of the control group (left leg), where EP was applied without sf-DNA. The SEAP activity in both the sf-DNA group and control group was detectable 1 day after EP-mediated transfection. It reached its peak by the seventh day, then steadily declined and persisted at a low level for the long term ( Figure 1b) . Although, compared with the control group, the activity of SEAP in the sf-DNA-based EP group increased about 3, 13, 12 and 6 times on the 1st, 3rd, 7th and 14th day, respectively, (P o 0.05).
The effect of sf-DNA on antigen protein expression of EP-mediated pCS immunization To determine whether sf-DNA-mediated EP results in high endogenous antigen expression, the ICR mice were vaccinated with pCS via gastrocnemius injection followed by EP. The HBsAg level in the treated muscle tissue was analyzed using enzymelinked immunosorbent assay (ELISA) kits and the results are presented in Figure 2 . The level of antigen in the EP group (8.2 ng) was much higher than that of i.m. injection without EP group. The sf-DNA added in pCS injection solution further increased the expression of HBsAg by ninefold and reached~76.5 ng in treated muscle. The sf-DNA also enhanced the expression of pCS immunized by EP when using a low voltage, 36 V (that is, 120 V cm − 1 ), and the level of HBsAg was~3.1 ng in the EP-only group and 18.5 ng in the sf-DNA-mediated EP group. A more interesting finding is that the HBsAg level in sf-DNA-mediated 120 V cm − 1 EP group was two times higher than that of 200 V cm − 1 EP group without sf-DNA. The effect of sf-DNA on humoral immune response of EP-mediated pCS immunization To test whether sf-DNA-mediated pCS EP immunization resulted in a stronger humoral response, the ICR mice were vaccinated with 5 μg pCS together with or without 10 μg 300 bp sf-DNA by EP, and the HBsAb level in serum was detected with ELISA kits in the 2nd, 3rd, 4th, 6th and 10th week after vaccination. The results presented in Figure 3a showed that the pCS administrated by i.m. without EP basically induced no humoral immune response. Meanwhile, 200 V cm − 1 electric pulses mediated pCS administration induced protective humoral immunity 2 weeks after vaccination (>10 mIU ml − 1 ), and then remained at a level of 20-40 mIU ml − 1 . The HBsAb level of the sf-DNA-mediated EP group quickly reached 50 mIU ml − 1 by just the second week, and reached 191, 266, 320 and 358 mIU ml − 1 by the 3rd, 4th, 6th and 10th week, respectively. The same effect of sf-DNA on immune enhancement was found when the EP was carried out using a low voltage of 36 V (that is, 120 V cm − 1 ). The results presented in Figure 3b showed that the HBsAb level in sf-DNA-mediated 120 V cm − 1 EP group was about six times that of 120 V cm
EP-only group, and also higher than that of 200 V cm − 1 EP group without the use of sf-DNA in all time points.
The effect of sf-DNA on cellular immune response of EP-mediated pCS immunization The cellular immune response was further tested using sf-DNA in EP-mediated pCS immunization. Five micrograms of pCS together with or without 10 μg 300 bp sf-DNA was administered into gastrocnemius using EP, and then the IFN-γ ELISpot assay was performed 2 weeks after the immunization. Regardless of which voltage was used in EP, the sf-DNA significantly enhanced the cellular immune responses induced by the pCS (Figure 4 ). There are The enhancement of DNA vaccine potency by EP is consistent with the efficient intracellular transfer of the plasmid DNA and the induction of acute inflammation and cell infiltration of EP-mediated DNA delivery. [33] [34] [35] [36] In this study, we used sf-DNA as helper molecules in EP-mediated gWIZ-GFP and pSEAP i.m. delivery. The results of in vivo imaging assay of GFP expressed in treated muscle and dynamic detection of SEAP secreted in serum validated that sf-DNA can significantly improve in vivo EP-mediated plasmid DNA delivery. These results are consistent with our previous study. 30 The mechanism may be correlated with the role of sf-DNA in the production of more effective electropores on membranes and the competitive protection of plasmid DNA from degradation or deactivation in interstitial fluid and cells, thereby allowing more plasmid DNA to enter muscle cells or to be taken up by inflammatory infiltration cells recruited by EP. 30, 37, 38 The effect of sf-DNA on EP-mediated plasmid DNA delivery suggests that sf-DNA may be an effective helper molecule for DNA immunization. Analysis of the HBV antigen expression showed that HBV DNA vaccine immunization with EP combined sf-DNA had a higher antigen expression compared with other groups. The elevated antigen induced a much quicker and higher specific antibody response compared with the group without sf-DNA. These results approved our speculation into the potency of sf-DNA on EP-mediated DNA vaccine immunization. Based on the fact that efficient antigen display is an indispensable requirement for T-cell induction, 39 the increased antigen abundance in the sf-DNA group may improve the strength of antigen presentation, and then induce a stronger cellular immune response than that in the normal EP immunization group. We observed that in comparison with the non-sf-DNA vaccination group, sf-DNA resulted in a threefold increase in HBsAg-specific IFN-γ-positive spleen cell in sf-DNA group. This notable increase in the IFN-γ-positive spleen cell indicates the considerable efficiency of sf-DNA on producing the cellular immune responses of EP-mediated DNA immunization.
Unlike the normal immunologic adjuvants such as CpG, cytokines and other immunomodulatory molecules or their expression vectors, 40, 41 sf-DNA is only used to facilitate the entrance of DNA vaccine into host cells and to improve the expression of specific antigen. At the same time, the sf-DNA used in this study is noncoding DNA fragment and would be degraded by deoxyribonuclease quickly in interstitial fluid and cells, minimizing the immunogenicity and potential insertion mutagenesis risk. In addition, we should note that sf-DNA is easy to prepare, with great stability at regular conditions, making it an ideal adjuvant for EP-mediated DNA vaccine immunization.
In current EP-mediated DNA immunization in big animal studies and clinical trials, an~200 V cm − 1 pulse voltage and milligram DNA vaccine doses were needed to achieve protective cellular and humoral immune responses. 17, 26, 35 An exciting finding in this study is that with the help of sf-DNA, the immune response level in the 120 V cm − 1 EP immunization group was higher than that of the 200 V cm − 1 group without the use of sf-DNA. This indicates that the sf-DNA-mediated EP could be an effective method to overcome the remaining issues of whether high-pulse voltage, high DNA vaccine dose and multiple vaccinations are still required to achieve considerable immune responses in big animals, so as to make the EP-mediated DNA vaccination more secure, economic and feasible for clinical application.
In conclusion, the results of the present study demonstrate that the use of sf-DNA significantly enhanced the level of antigen expressed in treated muscle. The elevated antigen induced higher and quicker immune responses of the EP-mediated DNA vaccination, indicating that sf-DNA can be used as an effective helper molecule to make EP-mediated DNA vaccination more effective and suitable for animal and clinical application. Future studies will focus on the potency of sf-DNA for EP-mediated DNA immunization in big animals.
MATERIALS AND METHODS Materials
Plasmid gWIZ-GFP encoding GFP was purchased from Gene Therapy Plasmid DNA encoding HBsAg preS2-S was constructed using the pcDNA3.1 vector, as described previously and named as pCS. 42 The SEAP reporter assay kit was the product of Toyobo Co., Ltd (Osaka, Japan). Threehundred base pairs sf-DNA was isolated and purified from sonicated salmon sperm DNA. The HBsAg and HBSAb ELISA kits were purchased from Shanghai Kehua Bio-Engineering Co., Ltd (Shanghai, China). The mouse lymphocyte separation medium and IFN-γ ELISpot kit were purchased from Dakewe Biotech Company Limited (Shenzhen, China). The HBsAg mouse epitope peptide with the sequence 'LTKILTIPQSLDSWWTSLN' was synthesized by Shenergy Biocolor Bioscience & Technology Co. (Shanghai, China) Animals Six-to eight-week-old female ICR mice were purchased from the Shanghai Laboratory Animal Center (Shanghai, China). All animal experiments were repeated at least twice with 6-9 mice in each group, and conducted in compliance with the guidelines and regulations of Shanghai Jiao Tong University and the China Council for Animal Care.
In vivo gWIZ-GFP EP delivery and optical imaging
After the mice were anesthetized with chloral hydrate (400 mg kg − 1 , Intraperitoneal injection), the skin over their gastrocnemius muscle was shaved. Next, a 40-μl solution containing 3 μg gWIZ-GFP together with or without 6 μg 300 bp sf-DNA was injected into the gastrocnemius tissues. Immediately after the injection, EP with six electric pulses was applied through a pair of silver electrodes spaced 3 mm apart covering the i.m. injection site. The electric pulses were 50 ms in duration and 1 s apart at a voltage of 60 V (that is, 200 V cm − 1 ). Twenty-four hours after the EP-mediated transfer of gWIZ-GFP, the mice were anesthetized and the GFP fluorescence imaging was acquired using an eXplore Optix in vivo fluorescence imaging system (ART Advanced Research Technologies, Inc., Montreal, QC, Canada) at 470 nm excitation and 525 nm emission filter.
In vivo pSEAP EP delivery and SEAP assay
After the mice were anesthetized, a 40-μl solution containing 5 μg pSEAP together with or without 10 μg 300 bp sf-DNA was injected into gastrocnemius tissues followed by EP with the parameters mentioned above. The blood samples were drawn at designated times after the EP-mediated plasmid transfection,and the sera were isolated and immediately frozen for future analysis. The SEAP activity was determined using the SEAP reporter assay kit, following the manufacturer's protocol.
Mice immunization
After the mice were anesthetized, a 40-μl solution containing 5 μg pCS together with or without 10 μg 300 bp sf-DNA was injected into their gastrocnemius tissues followed by EP according to the experimental protocol listed in Table 1 . The voltage used in a low voltage test was 36 V (that is, 120 V cm − 1 ).
HBsAg protein and HBsAb titers assay
Before and during the experiments, blood samples were drawn at designated times and sera were isolated and immediately frozen for future analysis. For muscle samples, the mice were killed 24 h after the EP-mediated transfer of pCS, and the entire muscle fiber were removed and homogenized in lysis buffer (Promega, Madison, WI, USA). The HBsAg in muscle sample and HBsAb titers in sera were measured using the corresponding ELISA kits. The HBsAg standards in μg ml − 1 and HBsAb standards in mIU ml − 1 were purchased from Sino-American Biotechnology Company (Luoyang, China). The antigen content and antibody titers were calculated based on the standard curve obtained.
IFN-γ ELISpot assay
The IFN-γ ELISpot assay was performed 2 weeks after the immunization using an ELISpot kit for mouse IFN-γ, as recommended by the manufacturer. Spleen cells were isolated from the vaccinated mice 2 weeks after immunization and washed three times in RPMI 1640 medium (HyClone, Logan, UT, USA). They were then plated into the ELISpot plates at the densities of 3 × 10 5 cells per well. HBsAg (10 μg ml -1 ) mouse epitope peptide (LTKILTIPQSLDSWWTSLN) was added to the culture plates for restimulation. In comparison, cells stimulated with 10 μg per well of phorbol 12-myristate 13-acetate and Ionomycin were used as positive control. After 48 h of incubation, the wells were emptied, washed with phosphate-buffered saline-Tween 20 and treated sequentially with biotinylated anti-mouse IFN-γ antibody, horseradish peroxidase-streptavidin and the substrate solution to reveal the spots. The developed microplates were analyzed by counting spots using an ELISpot Reader.
Statistical analysis
Data are presented as the mean ± s.d. The significance of the differences between individual groups was tested using the two-tailed t-test for unpaired values. Po0.05 was considered statistically significant. Abbreviations: i.m., intramuscular; pCS, plasmid DNA encoding HBV surface antigen preS2-S; sf-DNA, short noncoding DNA fragment.
